Radiotherapy for localized hormone-refractory prostate cancer in Japan

Katsumasa Nakamura, Teruki Teshima, Yutaka Takahashi, Atsushi Imai, Masahiko Koizumi, Norio Mitsuhashi, Yoshiyuki Shioyama, Toshihiko Inoue

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented. Materials and Methods: The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996-1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy. Results: Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1%), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively. Conclusion: Radiotherapy had an excellent local control rate for hormone-refractory cancer.

Original languageEnglish
Pages (from-to)3141-3145
Number of pages5
JournalAnticancer research
Volume24
Issue number5 B
Publication statusPublished - Sep 1 2004

Fingerprint

Prostatic Neoplasms
Japan
Radiotherapy
Hormones
Neoplasm Metastasis
Neoplasms
Lymph Nodes
Androgens
Disease-Free Survival
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakamura, K., Teshima, T., Takahashi, Y., Imai, A., Koizumi, M., Mitsuhashi, N., ... Inoue, T. (2004). Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer research, 24(5 B), 3141-3145.

Radiotherapy for localized hormone-refractory prostate cancer in Japan. / Nakamura, Katsumasa; Teshima, Teruki; Takahashi, Yutaka; Imai, Atsushi; Koizumi, Masahiko; Mitsuhashi, Norio; Shioyama, Yoshiyuki; Inoue, Toshihiko.

In: Anticancer research, Vol. 24, No. 5 B, 01.09.2004, p. 3141-3145.

Research output: Contribution to journalArticle

Nakamura, K, Teshima, T, Takahashi, Y, Imai, A, Koizumi, M, Mitsuhashi, N, Shioyama, Y & Inoue, T 2004, 'Radiotherapy for localized hormone-refractory prostate cancer in Japan', Anticancer research, vol. 24, no. 5 B, pp. 3141-3145.
Nakamura K, Teshima T, Takahashi Y, Imai A, Koizumi M, Mitsuhashi N et al. Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer research. 2004 Sep 1;24(5 B):3141-3145.
Nakamura, Katsumasa ; Teshima, Teruki ; Takahashi, Yutaka ; Imai, Atsushi ; Koizumi, Masahiko ; Mitsuhashi, Norio ; Shioyama, Yoshiyuki ; Inoue, Toshihiko. / Radiotherapy for localized hormone-refractory prostate cancer in Japan. In: Anticancer research. 2004 ; Vol. 24, No. 5 B. pp. 3141-3145.
@article{75e9189da8d24f91a0852ed5e6757f8e,
title = "Radiotherapy for localized hormone-refractory prostate cancer in Japan",
abstract = "Background: The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented. Materials and Methods: The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996-1998. Of them, 61 patients (19.6{\%}) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4{\%}) had T3-4 tumors and 15 (26.8{\%}) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy. Results: Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1{\%}), local progression was observed in one patient (1.6{\%}). The five-year overall and progression-free survival rates were 51.6{\%} and 43.5{\%}, respectively. Conclusion: Radiotherapy had an excellent local control rate for hormone-refractory cancer.",
author = "Katsumasa Nakamura and Teruki Teshima and Yutaka Takahashi and Atsushi Imai and Masahiko Koizumi and Norio Mitsuhashi and Yoshiyuki Shioyama and Toshihiko Inoue",
year = "2004",
month = "9",
day = "1",
language = "English",
volume = "24",
pages = "3141--3145",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Radiotherapy for localized hormone-refractory prostate cancer in Japan

AU - Nakamura, Katsumasa

AU - Teshima, Teruki

AU - Takahashi, Yutaka

AU - Imai, Atsushi

AU - Koizumi, Masahiko

AU - Mitsuhashi, Norio

AU - Shioyama, Yoshiyuki

AU - Inoue, Toshihiko

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background: The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented. Materials and Methods: The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996-1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy. Results: Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1%), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively. Conclusion: Radiotherapy had an excellent local control rate for hormone-refractory cancer.

AB - Background: The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented. Materials and Methods: The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996-1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy. Results: Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1%), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively. Conclusion: Radiotherapy had an excellent local control rate for hormone-refractory cancer.

UR - http://www.scopus.com/inward/record.url?scp=6344256564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344256564&partnerID=8YFLogxK

M3 - Article

C2 - 15510602

AN - SCOPUS:6344256564

VL - 24

SP - 3141

EP - 3145

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -